61
Participants
Start Date
November 5, 2024
Primary Completion Date
May 12, 2026
Study Completion Date
November 12, 2026
HMPL-760 planned dose 1
HMPL-760 planned dose 1 daily (QD) orally
R-GemOx
R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
HMPL-760 placebo planned dose 1
HMPL-760 placebo planned dose 1 daily (QD) orally
HMPL-760 planned dose 2
HMPL-760 planned dose 2 daily (QD) orally
HMPL-760 placebo planned dose 2
HMPL-760 placebo planned dose 2 daily (QD) orally
Fujian Medical University Union Hospital, Fuzhou
Sun Yat-sen University Cancer Center, Guangzhou
Guangxi Medical University Cancer Hospital, Nanning
Wuhan Union Hospital of China, Wuhan
Harbin First Hospital, Harbin
Harbin Medical University Cancer Hospital, Harbin
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Hunan Cancer Hospital, Changsha
Jiangxi Cancer Hospital, Nanchang
The First Affiliated Hospital of Nanchang University, Nanchang
Shengjing Hospital of China Medical University, Shenyang
Shandong Cancer Hospital & Institute, Jinan
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
West China Hospital of Sichuan University, Chengdu
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin
Lead Sponsor
Hutchmed
INDUSTRY